GlassScriptPhysician profile
Yu Zhao
NPI 1992148977
$12,791.48
in general payments reported to CMS, 2019-2025
74 companies · $3,799 in 2025
The $3,799 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $924 · 2021: $407 · 2022: $1,071 · 2023: $1,951 · 2024: $3,472 · 2025: $3,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,222.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,932.93 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Ucb, INC. | $788.54 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $676.27 | 2019-2025 | |
| Lundbeck LLC | $576.58 | 2019-2025 | Vyepti, Rexulti |
| Pfizer INC. | $534.15 | 2021-2025 | |
| Genentech USA, INC. | $515.08 | 2021-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Biogen, INC. | $514.13 | 2020-2025 | Tysabri, Vumerity, Skyclarys |
| Lilly USA, LLC | $415.90 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Emd Serono, INC. | $391.14 | 2019-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $390.17 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $378.50 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $317.34 | 2022-2025 | Xeomin |
| Amgen INC. | $263.77 | 2019-2025 | Uplizna |
| Sk Life Science, INC. | $242.11 | 2020-2025 | Xcopri |
| Celgene Corporation | $236.10 | 2022-2025 | Zeposia |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.